Ontology highlight
ABSTRACT:
SUBMITTER: Galvano A
PROVIDER: S-EPMC6700425 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
Galvano Antonio A Scaturro Dalila D Badalamenti Giuseppe G Incorvaia Lorena L Rizzo Sergio S Castellana Luisa L Cusenza Stefania S Cutaia Sofia S Santini Daniele D Guadagni Fiorella F Roselli Mario M Gori Stefania S Latteri Mario Adelfio MA Bazan Viviana V Giulia Letizia Mauro LM Russo Antonio A
Journal of bone oncology 20190716
Hormonal therapies for receptor positive-breast and prostate cancer patients have shown clinical efficacy but also several side effects including osteoporosis, loss of bone mass and increased fracture risk. Denosumab represents an anti RANKL (receptor activator of nuclear factor-kB ligand) monoclonal anti-body acting as inhibitor of osteoclasts formation, function, and survival, then increasing bone mass. Herein, we performed a systematic review and meta-analysis of randomized controlled trials ...[more]